title: The effect of entacapone on homocysteine levels in Parkinson disease.
authors.affiliation: Department of Neurology, University of California, San Francisco, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Ostrem
authors.forename: G A
authors.initials: GA
authors.lastname: Kang
authors.forename: I
authors.initials: I
authors.lastname: Subramanian
authors.forename: M
authors.initials: M
authors.lastname: Guarnieri
authors.forename: J
authors.initials: J
authors.lastname: Hubble
authors.forename: A L
authors.initials: AL
authors.lastname: Rabinowicz
authors.forename: J
authors.initials: J
authors.lastname: Bronstein
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism; D002230:Carbidopa / Q000494:pharmacology; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000494:pharmacology* / Q000627:therapeutic use; D015331:Cohort Studies; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006710:Homocysteine / Q000096:biosynthesis* / Q000097:blood; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D007980:Levodopa / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D006710:Homocysteine; D007980:Levodopa; C071192:entacapone; D002394:Catechol O-Methyltransferase; D002230:Carbidopa